COVID-19 Drug Associated APIs Market Size, Share, Growth Drivers, Trends And Analysis 2024-2033

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

COVID-19 Drug Associated APIs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $8.52 billion In 2028 At A CAGR Of 6.0% :

The covid-19 drug associated apis market size has grown strongly in recent years. It will grow from $6.37 billion in 2023 to $6.75 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising prevalence of covid-19, increasing awareness of covid-19 treatment options, expanding access to covid-19 drugs, growing demand for covid-19 drugs for prophylaxis, government initiatives, supply chain resilience.

The covid-19 drug associated apis market size is expected to see strongly grown in the next few years. It will grow to $8.52 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to development of new covid-19 drug modalities, increasing clinical trials for covid-19 drugs, rising demand for covid-19 vaccines, emerging variants, vaccination campaigns, pandemic preparedness. Major trends in the forecast period include customized api production, diversification of api sources, advanced manufacturing technologies, digitalization and data analytics, sustainability and green chemistry.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=3248&type=smp

COVID-19 Drug Associated APIs Market Major Segments
The covid-19 drug associated apis market covered in this report is segmented -

1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class
2) By Synthesis Type: Synthetic, Biotech
3) By Business Mode: Captive API, Merchant API

Key Driver - Elevated Demand For Active Pharmaceutical Ingredients (APIS) Driven By Antivirals, Antimalarials, And Respiratory Medications In The Covid-19 Drug Market

High demand for antiretrovirals, antimalarials, sedatives, bronchodilators, and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active components used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. FDA has approved Airsupra (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years of age and older. Favipiravir, which is used to treat influenza in Japan, has also shown a positive effect on COVID-19 patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for the COVID-19 drug associated APIs market over the forecast period.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=3248&type=smp

Prominent Trend - Pharmaceutical Industry's Strategic Expansion In Api Production To Meet Surging Demand For Covid-19 Drugs

Key players operating in the pharmaceutical industry that manufacture COVID-19 drug-associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For instance, in October 2023, Merck & Co., Inc., a US-based pharmaceutical company, with a recent partnership with the Heavy Water Board in India, hopes to tap into the deuterated raw compound industry, which is presently worth around $100 million and has the potential to rise to $1 billion over the next five to ten years. Merck seeks to support India's chemical, pharmaceutical, and technical sectors by offering high-quality compounds for the manufacture of medicines, semiconductors, OLEDs, and electronics. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients.

COVID-19 Drug Associated APIs Market Players
Major companies operating in the covid-19 drug associated apis market include Dr. Reddy's Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the COVID-19 drug-associated APIs market in 2023. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated apis market share during the forecast period. The regions covered in the covid-19 drug associated apis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. COVID-19 Drug Associated APIs Market Report Structure
3. COVID-19 Drug Associated APIs Market Trends And Strategies
4. COVID-19 Drug Associated APIs Market - Macro Economic Scenario
5. COVID-19 Drug Associated APIs Market Size And Growth
…..
27. COVID-19 Drug Associated APIs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.